沈慶坤

沈慶坤，1989年出生於山東聊城，醫學博士，延邊大學藥學院副教授、博士生導師，中國民族醫藥學會轉化醫學分會理事，吉林省藥物化學專業委員會委員，主要研究方向為抗腫瘤靶向藥物設計及天然產物結構修飾。

2011年畢業於中國藥科大學，2019年獲延邊大學藥物化學專業博士學位。2020年任延邊大學藥物化學系講師，2021年晉升副教授。主持國家自然科學基金項目、吉林省重點研發計畫醫藥專項、圖們江計畫、校級教研項目2項等科研項目，累計科研經費160餘萬元。以第一或通訊作者在《Journal of Medicinal Chemistry》《European Journal of Medicinal Chemistry》等期刊發表SCI論文22篇（中科院一區Top期刊12篇），獲授權專利8項，開發2個進入臨床前研究階段的候選化合物。獲吉林省“長白英才”青年拔尖人才、吉林省高層次引進人才D類、青年圖們江學者、青年圖們江學者B類及吉林省優秀博士畢業論文等榮譽。

基本介紹

• 中文名：沈慶坤
• 國籍：中國
• 民族：漢族
• 出生地：山東聊城
• 出生日期：1989年
• 畢業院校：延邊大學

人物經歷

2011年畢業於中國藥科大學，2019年畢於延邊大學，獲得醫學博士學位。2020年入職延邊大學，講師；2021年1月，延邊大學副教授。

研究方向

藥物化學，抗腫瘤靶向藥物及天然藥物研究

主要成就

主持國家自然科學基金1項、省重點研發計畫—醫藥專項1項，圖們江計畫2項、校級教研項目2項，累計獲得科研經費160餘萬，以第一或者通訊作者發表二區以上SCI論文22篇，其中J Med Chem、Eur J Med Chem等SCI中科院一區（Top期刊）12篇，獲得授權專利8項，獲得兩個候選化合物，處於處於臨床前研究階段。

【主持科研項目】

1. 基於p53-MDM2/HDACs雙靶點的冬凌草甲素衍生物的結構最佳化及抗腫瘤活性研究；國家自然科學基金，2021-2024年，82060628，34萬，已結項，主持

2. 雷公藤紅素類抗癌候選藥物S2109的臨床前研究；吉林省科技廳重點研發-醫藥健康關鍵技術研發項目，2024-2026年，20240305099YY, 90萬，在研，主持

3. 青年圖們江學者引進人才(2019年9月-2022年8月)，科研經費20萬, 已結項，主持

4. 基於p53-MDM2蛋白-蛋白相互作用的冬凌草甲素的結構修飾及抗腫瘤活性研究（JJKH20220559KJ）, 2022-01--2023-12, 2.5萬，已結項，主持

5. 延邊大學博士啟動基金，基於MDM2/HDACs雙靶點抑制作用的冬凌草甲素衍生物的結構修飾及抗腫瘤活性評價（602020087）, 2020-07--2023-07, 6萬，已結項，主持

【主持教研項目】

1、案例啟發式教學法在藥學專業本科教學中的探索與實踐，延邊大學2024年教學改革研究課題（202426）

2、新質生產力驅動下的“科教融合—拔尖創新”型研究生培養模式研究，2025年研究生教育教學改革研究課題（202525）

【近五年代表性論文】

(1) Fan-Fan Shang, Qing Lu, Tailiang Lin, Miaoxia Pu, Ruoxuan Xiao, Wanmei Liu, Hao Deng,Hongyan Guo, Zhe-Shan Quan, Chunyong Ding,*and Qing-Kun Shen*. Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry, 2023, 66: 12931-12949. (SCI 1區)

(2) Hao Deng , Qian Xu , Guo-Qing Chen, Xing Huang, Jin-Ying Liu, Ya-Lan Wang, Yin-Sheng Quan, Rui Yan, Zhe-Shan Quan**, Qing-Kun Shen*. Design and synthesis of azole derivatives of echinocystic acid as α-glucosidase inhibitors with hypoglycemic activity. European Journal of Medicinal Chemistry, 2025, 289: 117437. (SCI 1區)

(3) Hao Deng , Qian Xu , Xiao-Ting Li , Xing Huang, Jin-Ying Liu, Rui Yan, Zhe-Shan Quan*, Qing-Kun Shen*, Hong-Yan Guo*. Design, synthesis, and evaluation of antitumor activity in Pseudolaric acid B Azole derivatives: Novel and potent angiogenesis inhibitor via regulation of the PI3K/AKT and MAPK mediated HIF-1/VEGF signaling pathway. European Journal of Medicinal Chemistry, 2024, 278: 116813. (SCI 1區)

(4) Hong-Yan Guo, Xiaoting Li, Xiao-Tong Sang , Zhe-Shan Quan *, Qing-Kun Shen **. Design and synthesis of forsythin derivatives as anti-inflammatory agents for acute lung injury. European Journal of Medicinal Chemistry, 2024, 267: 116223. (SCI 1區)

(5) Zheng Liu, Xing Huang, Hong-Yan Guo, Lu-Wen Zhang, Yin-Sheng Quan,Fen-er Chen, Qing-Kun Shen**, Zhe-Shan Quan*. Design, synthesis fusidic acid derivatives alleviate acute lung injury via inhibiting MAPK/NF-κB/NLRP3 pathway. European Journal of Medicinal Chemistry, 2023, 259: 115697. (SCI 1區)

(6) Fan-Fan Shang, Jing Ying Wang, Qian Xu, Hao Deng, Hong-Yan Guo, Xuejun Jin, Xiaoting Li*, Qing-Kun Shen*, Zhe-Shan Quan*. Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1a pathway，European Journal of Medicinal Chemistry, 2021, 220：113474. (SCI 1區)

(7) Qing-Kun Shen, Hao Deng, Shi-Ben Wang, Yu-Shun Tian*, Zhe-Shan Quan*, Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway, European Journal of Medicinal Chemistry, 2019,173: 15-31. (SCI 1區)

(8) Lei Pang , Jin Li , Zheng Liu, Yin-Sheng Quan, He Huan Sui, Yi Jia , Fener Chen, Jung Joon Lee, Peng Liu, Zhe-Shan Quan, Qing-Kun Shen*, Hong-Yan Guo*. In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer’s disease，European Journal of Medicinal Chemistry, 2022, 224: 114825. (SCI 1區)

(9) Yin-Sheng Quan, Xiaoting Li, Lei Pang c, Hao Deng a, Fener Chen d, Jung Joon Lee, Zhe-Shan Quan, Peng Liu,*, Hong-Yan Guo*, Qing-Kun Shen*. Panaxadiol carbamate derivatives: Synthesis and biological evaluation as potential multifunctional anti-Alzheimer agents. Bioorganic Chemistry, 2024, 143: 106977 (SCI 1區).

(10) Xing Huang, Zheng Liu, Zhe-Shan Quan*, Hong-Yan Guo*, Qing-Kun Shen*. Synthesis and structure-activity relationship studies of fusidic acid derivatives as anti-inflammatory agents for acute lung injury. Bioorganic Chemistry, 2023, 141:106885 (SCI 1區).

(11) Hong-Yan Guo, ChunMei Jin, Hai-Ming Zhang, Chun-Mei Jin,* Qing-Kun Shen*, and Zhe-Shan Quan. Synthesis and Biological Evaluation of (+)-Usnic Acid Derivatives as Potential Anti-Toxoplasma gondii Agents, J Agric Food Chem, 2019, 67: 9630-9642. (SCI 1區)

(12) Hong-Yan Guo, Yue Xing, Yu-Qiao Sun, Can Liu, Qian Xu, Fan-Fan Shang, Run-Hui Zhang, Xue-Jun Jin, Fener Chen, Jung Joon Lee, Dongzhou Kang* , Qing-Kun Shen*, Zhe-Shan Quan*. Ginsengenin derivatives synthesized from 20(R)-panaxotriol:Synthesis, characterization, and antitumor activity targeting HIF-1 pathway. J Ginseng Res, 2022, 46, 738-749. (SCI 1區)

(13) Hao Deng, Qian Xu, Hong-Yan Guo, Xing Huang, Fener Chen, Lili Jin, Zhe-Shan Quan*, Qing-Kun Shen**, Application of cinnamic acid in the structural modification of natural products: A review, Phytochemistry, 2023, 206: 113532. (SCI 2區)

(14) Miao-Xia Pu, Hong-Yan Guo, Zhe-Shan Quan, Xiaoting Li and Qing-Kun Shen, Application of the Mannich reaction in the structural modification of natural products. J Enzyme Inhib Med Chem, 2023, 38(1): 2235095 (SCI 2區)

(15) Xing Huang, Hao Deng, Qing-Kun Shen*, Zhe-Shan Quan*,Tanshinone IIA: Pharmacology, total synthesis, and progress in structure-modifications, Curr Med Chem, 2022, 29: 1959-1989. (SCI 2區)

(16) Qing-Kun Shen; Guo-Hua Gong; Gao-Li; Mei-Jin; Li-Hua Cao and Zhe-Shan Quan, Discovery and evaluation of novel synthetic 5-alkyl-4-oxo- 4,5-dihydro-[1,2,4] triazolo[4,3-a]quinoxaline-1-carbox-amide derivatives as anti- inflammatory agents, J Enzyme Inhib Med Chem, 2020, 35(1): 85-95. (SCI 2區)

(17) Hong-Yan Guo, Zheng-Ai Chenb, Qing-Kun Shen* and Zhe-Shan Quan*, Application of triazoles in the structural modification of natural products., 2021, 36(1): 1115-1144. (SCI 2區)

【代表性授權專利】

1、沈慶坤，全哲山，尚凡凡，金學軍。一種雷公藤紅素衍生物及其製備方法和醫用用途。專利號：ZL 2021 1 0102947.3 (已授權，2022年2月25日)

2、沈慶坤，郭紅艷，全哲山，桑曉桐。一種連翹苷衍生物及其製備方法和醫用用途。專利號：ZL 2022 1 0450591.7 (已授權，2023年7月21)

3、沈慶坤，吳丹，全哲山。一種牛蒡子苷元衍生物、製備方法及套用。專利號：ZL 2022 1 1132063.3 （已授權，2024年3月1日）

所獲榮譽

吉林省“長白英才”青年拔尖人才、吉林省高層次引進人才D類、青年圖們江學者、青年圖們江學者B類（人才引進）、吉林省優秀博士畢業論文等榮譽。

社會任職

中國民族醫藥學會轉化醫學分會理事，吉林省藥物化學專業委員會委員。